Encountering COVID-19 as Endocrinologists
The world is entering an era of disaster and chaos due to coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2. Since its first emergence in December 2019 in Wuhan, China, COVID-19 has swept through Asia and propagated throughout the world to Europe and North America. As of April 13, 1,773,084 people were infected and 111,652 people had died from COVID-19 globally, and new record levels of infection are being reported every day. Based on the data that have been amassed so far, the primary risk factors for a severe disease course or even mortality from COVID-19 are underlying diseases such as diabetes and hypertension. As the global prevalence of diabetes continues to increase, patients with endocrine diseases such as diabetes mellitus and those who are on long-term corticosteroid therapy due to adrenal insufficiency or hypopituitarism are at risk for a poor prognosis of COVID-19. As endocrinologists, we would like to briefly review the current knowledge about the relationship between COVID-19 and endocrine diseases and to discuss what we can do for the safety and health of our patients with endocrine diseases in this globally threatening situation..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Endocrinology and Metabolism - 35(2020), 2, Seite 197-205 |
| Sprache: |
Englisch ; Koreanisch |
|---|
| Beteiligte Personen: |
Eun-Jung Rhee [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adrenal insufficiency |
|---|
| doi: |
10.3803/EnM.2020.35.2.197 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ076781011 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ076781011 | ||
| 003 | DE-627 | ||
| 005 | 20230309144844.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3803/EnM.2020.35.2.197 |2 doi | |
| 035 | |a (DE-627)DOAJ076781011 | ||
| 035 | |a (DE-599)DOAJ55946eeb0a7348b2b59e6333e431e771 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a kor | ||
| 050 | 0 | |a RC648-665 | |
| 100 | 0 | |a Eun-Jung Rhee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Encountering COVID-19 as Endocrinologists |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The world is entering an era of disaster and chaos due to coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2. Since its first emergence in December 2019 in Wuhan, China, COVID-19 has swept through Asia and propagated throughout the world to Europe and North America. As of April 13, 1,773,084 people were infected and 111,652 people had died from COVID-19 globally, and new record levels of infection are being reported every day. Based on the data that have been amassed so far, the primary risk factors for a severe disease course or even mortality from COVID-19 are underlying diseases such as diabetes and hypertension. As the global prevalence of diabetes continues to increase, patients with endocrine diseases such as diabetes mellitus and those who are on long-term corticosteroid therapy due to adrenal insufficiency or hypopituitarism are at risk for a poor prognosis of COVID-19. As endocrinologists, we would like to briefly review the current knowledge about the relationship between COVID-19 and endocrine diseases and to discuss what we can do for the safety and health of our patients with endocrine diseases in this globally threatening situation. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a endocrinologists | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a adrenal insufficiency | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a endocrine system diseases | |
| 653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
| 700 | 0 | |a Jung Hee Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Sun Joon Moon |e verfasserin |4 aut | |
| 700 | 0 | |a Won-Young Lee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Endocrinology and Metabolism |d Korean Endocrine Society, 2016 |g 35(2020), 2, Seite 197-205 |w (DE-627)DOAJ000066575 |x 20935978 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2020 |g number:2 |g pages:197-205 |
| 856 | 4 | 0 | |u https://doi.org/10.3803/EnM.2020.35.2.197 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/55946eeb0a7348b2b59e6333e431e771 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.e-enm.org/upload/pdf/EnM-2020-35-2-197.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2093-596X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2093-5978 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2020 |e 2 |h 197-205 | ||